emyria

12 November 2024

Shane Falconer
Senior Adviser, Listings Compliance
ASX Limited
Level 40, Central Park
152-158 St Georges Terrace
PERTH WA 6000

By email: ListingsCompliancePerth@asx.com.au

Dear Sir

EMYRIA LIMITED – Response to ASX Price Query

We refer to your price query letter to Emyria Limited (**EMD** or **Company**) dated 12 November 2024 and provides the following responses:

1. **Is EMD aware of any information concerning it that has not been announced to the market which, if known by some in the market, could explain the recent trading in its securities?**

   No, the Company is not aware of any information that has not been announced to the market which, if known, could explain the recent trading in its securities.

2. **If the answer to question 1 is "yes".**

   (a) Is EMD relying on Listing Rule 3.1A not to announce that information under Listing Rule 3.1? Please note that the recent trading in EMD's securities would suggest to ASX that such information may have ceased to be confidential and therefore EMD may no longer be able to rely on Listing Rule 3.1A. Accordingly, if the answer to this question is "yes", you need to contact us immediately to discuss the situation.

   (b) Can an announcement be made immediately? Please note, if the answer to this question is "no", you need to contact us immediately to discuss requesting a trading halt (see below).

   (c) If an announcement cannot be made immediately, why not and when is it expected that an announcement will be made?

   Not applicable.

3. **If the answer to question 1 is "no", is there any other explanation that EMD may have for the recent trading in its securities?**

   The Company notes there has been recent media speculation regarding potential policy shifts by the incoming Trump administration in the United States of America, which may favour the use of psychedelics in therapeutic settings. It is possible that this speculation may have drawn increased public interest in the Company's securities. The Company is

also aware it is the only ASX-listed Company actively involved in the provision and evaluation of psychedelic-assisted therapies and the Company recently advised that it has received ethics endorsement for its new psilocybin-assisted therapy program (refer ASX announcement of 28 October 2024). However, the media speculation is uncertain and in any event, concerns the industry as a whole rather than EMD in particular. The Company is not aware of any other explanation for the recent trading activity in its securities.

In EMD's quarterly cash flow report announced on 30 October 2024 for the quarter ending 30 September 2024, based on estimates from its tax advisors, EMD disclosed that it is anticipating an R&D Tax Incentive refund of $1,461,770, with approximately $640,000 expected in net cash after the Radium Loan is repaid. EMD still anticipates the receipt of the R&D Tax Incentive, however if required, the directors of EMD continue to consider the optimum timing for an equity capital raising. At present, the timing of such a raise is not known, no mandate has been entered into and no indicative raising price has been set.

4. Please confirm that EMD is complying with the Listing Rules and, in particular, Listing Rule 3.1.

The Company confirms that it has at all times complied with, and continues to comply with, the ASX Listing Rules and in particular Listing Rule 3.1.

5. Please confirm that EMD's responses to the questions above have been authorised and approved under its published continuous disclosure policy or otherwise by its board or an officer of EMD with delegated authority from the board to respond to ASX on disclosure matters.

The Company confirms that the responses to the questions above have been authorised and approved in accordance with its published continuous disclosure policy, or otherwise by its board or an officer with delegated authority from the board to respond to ASX on disclosure matters.

By order of the Board



Susan Park
Company Secretary

12 November 2024

Reference: 103106

Ms Susan Park
Company Secretary
Emyria Limited

By email: spark@parkadvisory.com.au

Dear Ms Park

Emyria Limited ('EMD'): Price - Query

ASX refers to the following:

A. The change in the price of EMD's securities from a low of $0.031 from commencement of trade yesterday, 11 November 2024 to an intraday high of $0.044 today, 12 November 2024.

B. The significant increase in the volume of EMD's securities traded from commencement of trade today, 12 November 2024.

Request for information

In light of this, ASX asks EMD to respond separately to each of the following questions and requests for information:

1. Is EMD aware of any information concerning it that has not been announced to the market which, if known by some in the market, could explain the recent trading in its securities?

2. If the answer to question 1 is "yes".

    (a) Is EMD relying on Listing Rule 3.1A not to announce that information under Listing Rule 3.1? Please note that the recent trading in EMD's securities would suggest to ASX that such information may have ceased to be confidential and therefore EMD may no longer be able to rely on Listing Rule 3.1A. Accordingly, if the answer to this question is "yes", you need to contact us immediately to discuss the situation.

    (b) Can an announcement be made immediately? Please note, if the answer to this question is "no", you need to contact us immediately to discuss requesting a trading halt (see below).

    (c) If an announcement cannot be made immediately, why not and when is it expected that an announcement will be made?

3. If the answer to question 1 is "no", is there any other explanation that EMD may have for the recent trading in its securities?

4. Please confirm that EMD is complying with the Listing Rules and, in particular, Listing Rule 3.1.

5. Please confirm that EMD's responses to the questions above have been authorised and approved under its published continuous disclosure policy or otherwise by its board or an officer of EMD with delegated authority from the board to respond to ASX on disclosure matters.

When and where to send your response

This request is made under Listing Rule 18.7. Your response is required as soon as reasonably possible and, in any event, by no later than **12PM AWST Tuesday, 12 November 2024**. You should note that if the information

requested by this letter is information required to be given to ASX under Listing Rule 3.1 and it does not fall within the exceptions mentioned in Listing Rule 3.1A, EMD's obligation is to disclose the information 'immediately'. This may require the information to be disclosed before the deadline set out in the previous paragraph and may require EMD to request a trading halt immediately.

Your response should be sent to me by e-mail at **ListingsCompliancePerth@asx.com.au**. It should not be sent directly to the ASX Market Announcements Office. This is to allow me to review your response to confirm that it is in a form appropriate for release to the market, before it is published on the ASX Market Announcements Platform.

Trading halt

If you are unable to respond to this letter by the time specified above, or if the answer to question 1 is "yes" and an announcement cannot be made immediately, you should discuss with us whether it is appropriate to request a trading halt in EMD's securities under Listing Rule 17.1. If you wish a trading halt, you must tell us:

- the reasons for the trading halt;
- how long you want the trading halt to last;
- the event you expect to happen that will end the trading halt;
- that you are not aware of any reason why the trading halt should not be granted; and
- any other information necessary to inform the market about the trading halt, or that we ask for.

We require the request for a trading halt to be in writing. The trading halt cannot extend past the commencement of normal trading on the second day after the day on which it is granted. You can find further information about trading halts in Guidance Note 16 *Trading Halts & Voluntary Suspensions*.

Suspension

If you are unable to respond to this letter by the time specified above, ASX will likely suspend trading in EMD's securities under Listing Rule 17.3.

Listing Rules 3.1 and 3.1A

In responding to this letter, you should have regard to EMD's obligations under Listing Rules 3.1 and 3.1A and also to Guidance Note 8 *Continuous Disclosure*: Listing Rules 3.1 – 3.1B. It should be noted that EMD's obligation to disclose information under Listing Rule 3.1 is not confined to, nor is it necessarily satisfied by, answering the questions set out in this letter.

Release of correspondence between ASX and entity

ASX reserves the right to release all or any part of this letter, your reply and any other related correspondence between us to the market under Listing Rule 18.7A.

Yours sincerely

ASX Compliance